Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712.
N Engl J Med. 2021.
PMID: 33789010
Clinical Trial.